RxDoctor Payments Data

John Shaw, MD

Internal Medicine · Nashville, TNNPI 1245300391

Payments from drug & device makers

$2,521in general payments, 2019–2025

Across 124 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$349
  • AstraZeneca$340
  • Novo Nordisk$293
  • Pfizer$263
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$177
  • Astellas Pharma US Inc$123
  • plus $977 from 20 others

What the payments were for

  • Food & beverage$2,521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,521 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$94,095
Medicare patients
239
Services billed
1,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$133,715
MounjaroTirzepatide81$97,793
EliquisApixaban106$88,080
TrulicityDulaglutide43$55,515
XareltoRivaroxaban50$42,744
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$32,610
JardianceEmpagliflozin41$32,008
FarxigaDapagliflozin Propanediol45$31,283
Xigduo XrDapaglifloz Propaned/Metformin18$20,188
Synjardy XrEmpagliflozin/Metformin Hcl12$15,912
EntrestoSacubitril/Valsartan16$11,872
ValiumDiazepam12$10,678
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,723
Praluent PenAlirocumab17$9,160
LinzessLinaclotide13$8,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$98$153,307124 claims
Novo NordiskOzempic$293$133,71595 claims
PfizerEliquis, Paxlovid$263$90,816132 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere$340$49,46782 claims
GSKTrelegy Ellipta, Anoro Ellipta$72$38,44157 claims
AbbVieLinzess, Synthroid$349$11,42944 claims
Sumitomo Pharma America, Inc.Gemtesa$15$6,86511 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$39$4,75912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →